Latest Asx Companies News

ClearView Wealth Limited reported strong second-half growth in FY25, with underlying NPAT up 11% and life insurance margins rebounding. The company is poised for further expansion in FY26, backed by technology upgrades and strategic simplification.

InvestSMART Group has showcased its position as Australia’s leading direct-to-investor digital wealth platform, reporting $711 million in funds under management and highlighting its integrated ecosystem of low-cost funds, research, and tools.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Sandon Capital Investments reports a robust 72% increase in net profits, driven by a 32.2% portfolio return that more than doubles market performance, alongside a healthy fully franked dividend yield.

Star Minerals Limited addresses a sharp rise in its share price and trading volume, attributing the movement to pending assay results from recent drilling activities. The company confirms compliance with ASX disclosure rules while preparing to release interpreted data.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Miramar Resources has extended its Share Purchase Plan closing date to 27 August 2025, giving shareholders more time to invest at a 20% discount as the company awaits critical exploration results.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

RBR Group stands uniquely positioned as the only ASX-listed company directly linked to Mozambique’s LNG megaprojects, gearing up for a sector revival and broader African growth.

ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.

Pro Medicus Limited has renewed a significant five-year contract with Franciscan Missionaries of Our Lady Health System, marking a strategic shift to cloud-based medical imaging solutions and promising new revenue streams.